Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Patients with IBS-D treated with eluxadoline achieve better clinical response

Patients with diarrhea-predominant irritable bowel syndrome, or IBS-D, treated with eluxadoline achieved better clinical response and experienced more symptom improvement than those using placebo, according to a recent study in Gastroenterology, the official journal of the American Gastroenterological Association. Eluxadoline, which is currently in phase 3 trials, is under development as a potential treatment for IBS-D.

13 Aug 2013

Children born by Caesarean section more vulnerable to allergies

Children who came into the world by Caesarean section are more often affected by allergies than those born in the natural way. The reason for this may be that they have a less diverse gut microbiota, according to a study by universities in Sweden and Scotland.

9 Aug 2013

Researchers develop reliable way to use finger-stick blood sample to detect fibromyalgia syndrome

Researchers have developed a reliable way to use a finger-stick blood sample to detect fibromyalgia syndrome, a complicated pain disorder that often is difficult to diagnose.

24 Jul 2013

Fibromyalgia diagnosis: an interview with Dr. Bruce Gillis, CEO of EpicGenetics

Presently, it is a diagnosis of exclusion. Patients end up spending, according to what’s been published in the medical literature, as many as 3 - 5 years going from doctor to doctor seeking a diagnosis because they tend to have nonspecific symptoms of a subjective nature.

23 Jul 2013

UCI-led study point to new approach for treating foodborne illnesses

UC Irvine microbiologists have learned how a probiotic bacterium used to treat irritable bowel syndrome can soothe gut bacterial infections caused by Salmonella, paving the way for potential relief from foodborne illnesses that affect millions of people annually.

18 Jul 2013

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.

16 Jul 2013

Endoscopic imaging: an interview with Len Farris, Vice President of Marketing, Americas, PENTAX Medical

The impact of endoscopic imaging on patient care has been enormous since the first fiber optic systems were introduced more than 50 years ago. Today, high resolution and high definition systems are used to provide clinicians and patients unprecedented images from inside the body.

From PENTAX Medical Company 3 Jul 2013

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Soligenix, Inc. (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

1 Jul 2013

Constella® (linaclotide), for the symptomatic treatment of Irritable Bowel Syndrome with Constipation (IBS-C), is now available in Germany, UK and Nordic countries

Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced the launch of Constella® (linaclotide 290mcg capsules once daily), the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe IBS-C,(1) in Europe. Constella® is now available in Germany, the UK and Nordic countries and is expected to be launched in several other European countries in 2013.

13 Jun 2013

Study: 3/4 women experience constipation and other bowel disorders during their pregnancies

Nearly three out of four pregnant women experience constipation, diarrhea or other bowel disorders during their pregnancies, a Loyola University Medical Center study has found.

21 May 2013

Research explores pharmaceutical advances for IBS, hepatitis C

Research presented at Digestive Disease Week explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea and hepatitis C.

21 May 2013

Study examines self-management support in primary care

The processes to allow people to self-manage their own illness are not being used appropriately by health professionals to the benefit of their patients, new research suggests.

18 May 2013

Changes in specific proteins contribute to 'leaky-gut' wall

Scientists at Trinity College Dublin have made an important advance in understanding the biological factors that keep the lining of the gut wall intact. Associate Professor, Maria O'Sullivan at Trinity's School of Medicine and St James's Hospital and colleagues, showed that changes in specific proteins may contribute to a 'leaky-gut' wall which may have important implications for common chronic digestive diseases such as irritable bowel syndrome and inflammatory bowel disease.

17 May 2013

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

15 May 2013

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial.

10 May 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

Schizophrenia cardiovascular risk under-recognized in primary care

UK researchers have found that despite being a major contributor to premature deaths among patients with schizophrenia, cardiovascular disease is less likely to be recorded on their primary care records than those of people without schizophrenia.

30 Apr 2013

Schizophrenia cardiovascular risk under-recognized in primary care

25 Apr 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

Rhythm starts RM-131 Phase 2 clinical trial for treatment of chronic constipation

Rhythm announced today the initiation of an additional Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of chronic constipation. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal motility.

16 Apr 2013

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Patients with IBS-D treated with eluxadoline achieve better clinical response

Children born by Caesarean section more vulnerable to allergies

Researchers develop reliable way to use finger-stick blood sample to detect fibromyalgia syndrome

Fibromyalgia diagnosis: an interview with Dr. Bruce Gillis, CEO of EpicGenetics

UCI-led study point to new approach for treating foodborne illnesses

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Endoscopic imaging: an interview with Len Farris, Vice President of Marketing, Americas, PENTAX Medical

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Constella® (linaclotide), for the symptomatic treatment of Irritable Bowel Syndrome with Constipation (IBS-C), is now available in Germany, UK and Nordic countries

Study: 3/4 women experience constipation and other bowel disorders during their pregnancies

Research explores pharmaceutical advances for IBS, hepatitis C

Study examines self-management support in primary care

Changes in specific proteins contribute to 'leaky-gut' wall

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Schizophrenia cardiovascular risk under-recognized in primary care

Schizophrenia cardiovascular risk under-recognized in primary care

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Rhythm starts RM-131 Phase 2 clinical trial for treatment of chronic constipation

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in